Controlled chemoprophylaxis trials in tuberculosis. A general review.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000413:Alaska; D000740:Anemia / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity; D004352:Drug Resistance, Microbial; D004827:Epilepsy / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006116:Greenland; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D007564:Japan; D007630:Kenya; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced; D009426:Netherlands; D009518:New York; D010679:Philippines; D010919:Placebos; D011247:Pregnancy / Q000187:drug effects; D014374:Tuberculin Test; D014376:Tuberculosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control; D014416:Tunisia; D014481:United States; D014492:United States Public Health Service
D010919:Placebos; D007538:Isoniazid